Novo Nordisk pediatric win

Novo Nordisk said Thursday its diabetes pill semaglutide lowered blood sugar in children and teens with type 2 diabetes in a late-stage trial. (finance.yahoo.com) In the Phase 3a PIONEER TEENS study, the pill cut hemoglobin A1c — a three-month average of blood sugar — by 0.83 percentage points versus placebo after 26 weeks. The trial enrolled patients ages 10 to 17. (biospace.com) Novo Nordisk said PIONEER TEENS was the first clinical trial of an oral glucagon-like peptide-1 receptor agonist, or GLP-1 drug, in children and adolescents with type 2 diabetes. The company said it plans to file for label expansions for Ozempic pill and Rybelsus in the United States and European Union in the second half of 2026. (mfn.se) Type 2 diabetes in children is a smaller market than adult obesity and diabetes, but treatment options are limited and the disease can progress for decades. An oral drug also offers an alternative to injections for families managing chronic care. (finance.yahoo.com) The readout also lands as drugmakers and suppliers are trying to show the GLP-1 boom extends beyond weight-loss headlines. West Pharmaceutical raised its 2026 profit and revenue forecasts on Thursday, citing demand for proprietary products including syringes and cartridges used for injectable drugs. (finance.yahoo.com) Reuters reported Novo Nordisk shares were little changed after the trial result, a sign investors had focused more on the company’s broader obesity and diabetes franchise than on this pediatric update alone. West Pharmaceutical shares rose nearly 13% before the bell after its forecast increase. (msn.com; srnnews.com) For Novo Nordisk, the next step is regulatory review, not a launch yet. Thursday’s result gives the company data to take to U.S. and European regulators as it tries to extend semaglutide into younger patients. (biospace.com)